Oncolytics Biotech, Inc. (USA)  

(Public, NASDAQ:ONCY)   Watch this stock  
Find more results for oncy
0.575
+0.045 (8.49%)
Aug 28 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.54 - 0.59
52 week 0.40 - 1.42
Open 0.54
Vol / Avg. 277,228.00/306,589.00
Mkt cap 62.58M
P/E     -
Div/yield     -
EPS -0.12
Shares 117.98M
Beta 3.02
Inst. own 1%
Nov 4, 2015
Q3 2015 Oncolytics Biotech Inc Earnings Release (Estimated) Add to calendar
Sep 10, 2015
Oncolytics Biotech Inc at Robert W Baird and Co Health Care Conference - 10:50AM EDT - Add to calendar
Aug 13, 2015
Oncolytics Biotech Inc at Canaccord Genuity Growth Conference
Aug 6, 2015
Q2 2015 Oncolytics Biotech Inc Earnings Release
Jun 18, 2015
Oncolytics Biotech Inc Annual Shareholders Meeting (Estimated)
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -47.79% -82.00%
Return on average equity -53.90% -103.35%
Employees 22 -
CDP Score - -

Address

Suite 210, 1167 Kensington Crescent NW
CALGARY, AB T2N 1X7
Canada
+1-403-6707377 (Phone)
+1-403-2830858 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Oncolytics Biotech Inc. (Oncolytics) is a development-stage company. The Company is focused on research and development of REOLYSIN, which is its cancer therapeutic. REOLYSIN is developed from reovirus. Oncolytics is directing a clinical trial program with the focus of developing REOLYSIN as a human cancer therapeutic. The clinical program includes clinical trials, which it sponsors directly along with Third Party Clinical Trials. Third Party Clinical Trials are clinical trials that are being sponsored by other institutions. Its clinical trial program includes human trials using REOLYSIN alone, and in combination with radiation and chemotherapy, and delivered via local administration and/or intravenous administration. Oncolytics uses contract toll manufacturers to produce REOLYSIN. The Company has two subsidiaries: Oncolytics Biotech (Barbados) Inc. (OBB), a Barbados company, and Valens Pharma Ltd. Oncolytics Biotech (US) Inc. and Oncol

Officers and directors

Bradley G. Thompson Ph.D. Executive Chairman of the Board, President, Chief Executive Officer
Bio & Compensation  - Reuters
Kirk J. Look Chief Financial Officer
Bio & Compensation  - Reuters
Matthew C. Coffey Ph.D. Chief Operating Officer, Director
Bio & Compensation  - Reuters
George M. Gill M.D. Senior Vice President - Regulatory Affairs & Chief Safety Officer
Bio & Compensation  - Reuters
Alan J. Tuchman M.D. Chief Medical Officer, Senior Vice President - Medical and Clinical Affairs
Age: 68
Bio & Compensation  - Reuters
Mary Ann Dillahunty J.D. Vice President - Intellectual Property
Bio & Compensation  - Reuters
Robert B. Schultz Lead Independent Director
Bio & Compensation  - Reuters
Angela Frances Holtham Director
Bio & Compensation  - Reuters
Edwin Levy Ph.D. Director
Bio & Compensation  - Reuters
J. Mark Lievonen Director
Bio & Compensation  - Reuters